Review



double gradient heatmap plot  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc double gradient heatmap plot
    (A) <t>Heatmap</t> of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.
    Double Gradient Heatmap Plot, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/double gradient heatmap plot/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    double gradient heatmap plot - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells"

    Article Title: Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0268635

    (A) Heatmap of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.
    Figure Legend Snippet: (A) Heatmap of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.

    Techniques Used: Knockdown, Mutagenesis, Concentration Assay, Activity Assay, Control, Western Blot



    Similar Products

    double gradient heatmap plot  (GraphPad Software Inc)
    90
    GraphPad Software Inc double gradient heatmap plot
    (A) <t>Heatmap</t> of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.
    Double Gradient Heatmap Plot, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/double gradient heatmap plot/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    double gradient heatmap plot - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Heatmap of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.

    Journal: PLoS ONE

    Article Title: Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells

    doi: 10.1371/journal.pone.0268635

    Figure Lengend Snippet: (A) Heatmap of ATARiS gene sensitivity scores of two KRAS dependent cell lines (NCI-H358 and MDA-MB-231) and a BRAF dependent cell line (A375). Negative values (shaded red) indicate sensitivity of the cell line proliferation to the knockdown of shown genes, whereas positive scores (shaded blue) indicate insensitivity. (B) IC 50 values for indicated compounds in Ras pathway mutant cell lines NCI-H358, MDA-MB231 and A375 grown as 3D spheroids under serum free conditions. Compounds were tested either as single agent at a concentration range of 0.2 μM– 10 μM (calmidazolium), 0.6 μM– 40 μM (DT-061), 0.2 μM– 40 μM (trifluoperazine) and 0.6 μM– 40 μM (ARS-1620) or in combination, applying the whole concentration range of calmidazolium combined with 1 μM or 2 μM of DT-061, as indicated. Data represent mean values ± SD, n = 2. Statistical comparisons were done using the average values across all three cell lines. (C) Bliss synergism scores for combinatorial effects of calmidazolium and DT-061 in KRAS- or BRAF-mutant cancer cell lines. Data represent mean values ± SD, n = 2. Positive scores indicate synergistic drug interactions whereas negative scores would denote antagonistic drug interactions. A score of zero would indicate no antagonistic or synergistic effect. ( D ) Flow cytometric analysis of apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were treated with DT-061 (10 μM) or calmidazolium (5 μM) or their combination for 24 h and then labelled with Annexin V-FITC and 7AAD. Benzethonium chloride and DMSO treated cells were used as positive and negative controls, respectively, for setting the gates. Percentage of total apoptotic cells (early and late stage) from two biological repeats (mean ± SD) is presented. Statistical analysis was performed using Fisher’s exact test comparing the total number of viable and apoptotic cells from two biological repeats. ( E ) Effect of inhibitors on cellular apoptosis studied using Caspase-3/7Glo assay. MDA-MB-231 cells were treated with DT-061 (5 μM), calmidazolium (5 μM), combination of DT-061 and calmidazolium (5 μM each), and staurosporine (1 μM) for 24 h. The caspase-3/7 activity was measured as a luminescence read-out and normalized to the vehicle control, 0.05% (v/v) DMSO. Data represent mean values ± SD, n = 2. ( F ) Western blot analysis of PARP-cleavage activity in MDA-MB-231 cells treated with DMSO (0.2% (v/v)), DT-061 (20 μM), calmidazolium (5 μM), combinations of DT-061 (10 μM) and calmidazolium (5 μM), and staurosporine (1 μM) for 24 h. GAPDH detection was used as loading control.

    Article Snippet: The normalized viability data for the siRNA knockdown of each gene of interest were downloaded from the project DRIVE and a double gradient heatmap plot was generated using Prism (GraphPad).

    Techniques: Knockdown, Mutagenesis, Concentration Assay, Activity Assay, Control, Western Blot